Nitrates: Why and how should they be used today?
- 1 January 1990
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 38 (S1) , S35-S51
- https://doi.org/10.1007/bf01417564
Abstract
Nitrates are highly effective both in terminating acute attacks of angina pectoris and in the prophylaxis of symptomatic and asymptomatic myocardial ischemia. Preload reduction by venodilatation is the prevailing mechanism of nitrates in patients with chronic stable angina and is the unique feature distinguishing them from beta and calcium-channel blockers. Nitrates dilate coronary arteries not only in pre- and poststenotic vessels, but also in eccentric lesions. In patients with endothelial dysfunction, nitrates seem to be the physiological substitute for endothelium-derived relaxing factor. During the past decade, however, there has been substantial evidence of a clinically relevant loss of the anti-ischemic effects (“nitrate tolerance”). Many studies with oral dosing of isosorbide dinitrate or isosorbide-5-mononitrate at least three times daily have proven nitrate tolerance in patients with coronary artery disease and/or congestive heart failure. Complete loss of anti-ischemic effects after repetitive, continuous patch attachments has also been found. As we first showed in 1983, intermittent therapy with once-daily ingestion of high-dose sustained-release isosorbide dinitrate was successful in preventing the development of tolerance. Similarly, tolerance to isosorbide-5-mononitrate also does not develop when it is ingested once daily. It is now generally accepted that a daily low-nitrate interval is required to prevent tolerance development. Although the minimal patch-free interval required to prevent tolerance needs further investigation, a 12-h patch-free interval should prevent tolerance in most patients. The prolonged duration of action of once-daily high-dosage administration of sustained-release formulations, the improved patient compliance with a single daily administration, and the increased likelihood of maximal anti-ischemic effects are important reasons for recommending high single daily doses of isosorbide dinitrate or isosorbide-5-mononitrate.Keywords
This publication has 214 references indexed in Scilit:
- Mental Stress and the Induction of Silent Myocardial Ischemia in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1988
- Reversal of Nitrate Tolerance withN-AcetylcysteineNew England Journal of Medicine, 1988
- In Vivo Induction and Reversal of Nitroglycerin Tolerance in Human Coronary ArteriesNew England Journal of Medicine, 1987
- Prevention and Reversal of Nitrate Tolerance in Patients with Congestive Heart FailureNew England Journal of Medicine, 1987
- Paradoxical Vasoconstriction Induced by Acetylcholine in Atherosclerotic Coronary ArteriesNew England Journal of Medicine, 1986
- Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart FailureNew England Journal of Medicine, 1986
- Silent Ischemia as a Marker for Early Unfavorable Outcomes in Patients with Unstable AnginaNew England Journal of Medicine, 1986
- Sustained hemodynamic and antianginal effect of high dose oral isosorbide dinitrate.Circulation, 1977
- Radionuclide assessment of nitroglycerin influence on abnormal left ventricular segmental contraction in patients with coronary heart disease.Circulation, 1976
- Comparative hemodynamic effects of chewable isosorbide dinitrate and nitroglycerin in patients with congestive heart failure.Circulation, 1975